你知道吗？在抗癌药物研发领域，有一款来自中国成都的创新生物药正在书写新的篇章。4月8日，百利天恒宣布了一项令人振奋的消息：其自主研发的注射用BL-B01D1针对特定类型的尿路上皮癌患者已经完成了首例受试者入组，这标志着这款全球首创的新概念双抗ADC药物又迈出了坚实的一步。

Vantage Market Research report examines the Antibody Drug Conjugates (ADCs) market, forecasting trends and dynamics from 2025 ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid ...

今日（3月26日），基石药业宣布，其5款自主研发创新药物的最新临床前研究成果将同时亮相2025年美国癌症研究协会（AACR）年会，包括 三抗 CS2009、 双抗 CS2011及 三款创新抗体偶联药物（ADC） CS5006、CS5007与CS5005。相关研究摘要将于美国东部时间4月11日发表于AACR官方期刊 Cancer Research。

迈威生物 (688062.SH)，一家全产业链布局的创新型生物制药公司， 宣布将于当地时间 2025 年 4 月 25-30 日在美国芝加哥举行的 2025 年美国癌症研究协会 (AACR) 年会，以壁报形式公布 6 项研究成果 。

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

Steen Lisby, M.D., D.MSc. joins as Chief Medical OfficerJesper Valbjørn, M.Sc. joins as Senior Vice President CMCOngoing team expansion at Myricx Bio's new facilities in London’s Canary Wharf biotech ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...